Allen Capital Group LLC Increases Stake in Novo Nordisk A/S $NVO

Allen Capital Group LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 29.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,191 shares of the company’s stock after buying an additional 16,727 shares during the quarter. Allen Capital Group LLC’s holdings in Novo Nordisk A/S were worth $2,727,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NVO. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Novo Nordisk A/S by 5.1% in the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after purchasing an additional 717,719 shares during the last quarter. Morgan Stanley raised its holdings in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $287,660,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVO. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Five investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Novo Nordisk A/S Stock Down 8.5%

Shares of NYSE NVO opened at $47.20 on Friday. The business has a 50-day moving average price of $46.92 and a 200 day moving average price of $45.50. The stock has a market cap of $210.74 billion, a PE ratio of 11.08, a price-to-earnings-growth ratio of 4.71 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.